To NASDAQ OMX Copenhagen A/S
Announcement No. 25-10 / Copenhagen, 17 September 2010
Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.Topotarget.com
Report pursuant to the Danish Securities Trading Act, Section 28a
Copenhagen - 17 September 2010 - Pursuant to the Danish Securities Trading Act,
Section 28a Topotarget A/S (OMX: TOPO) is obliged to report on transactions by
members of its board of directors and senior management as well as their
related parties in shares issued by Topotarget A/S and related securities.
Name Jesper Bo Hansen
Reason Chairman
Issuer and ISIN code Topotarget A/S, DK0060003556
Transaction Purchase
Trade date 16 September 2010
Market Copenhagen Stock Exchange
Number 300,000
Market value in DKK 1,110,000
Name Ingelise Saunders
Reason Board Member
Issuer and ISIN code Topotarget A/S, DK0060003556
Transaction Purchase
Trade date 16 September 2010
Market Copenhagen Stock Exchange
Number 25,000
Market value in DKK 92,500
Name Anker Lundemose
Reason Board Member
Issuer and ISIN code Topotarget A/S, DK0060003556
Transaction Purchase
Trade date 16 September 2010
Market Copenhagen Stock Exchange
Number 15,000
Market value in DKK 55,500
Name Anders Vadsholt
Reason Chief Financial Officer
Issuer and ISIN code Topotarget A/S, DK0060003556
Transaction Purchase
Trade date 16 September 2010
Market Copenhagen Stock Exchange
Number 25,000
Market value in DKK 92,500
Topotarget A/S
For further information, please contact:
Francois Martelet, CEO: Direct: +45 39 17 94 99; Mobile: +45 31 36 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55
Background information
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Scandinavian based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary (CUP).
Topotarget's key cancer drugs target HDAC, NAD+, mTOR, Fas ligand and
topoisomerase II. Savene®/Totect® is the first product on the market from
Topotarget's drug discovery technology. Totect® is marketed by the company's
own sales specialists in the US. The European rights to, Savene®, were divested
in March 2010 as a consequence of the focus to develop and commercialise
belinostat. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.
